NEW YORK – Novellus on Monday said it is working with Tempus to accelerate patient enrollment for its BRAF inhibitor program.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.